We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    elamipretide | Barth syndrome

An Intermediate Size Expanded Access Protocol of Elamipretide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04689360
Expanded Access Status : Available
First Posted : December 30, 2020
Last Update Posted : November 8, 2021
Information provided by (Responsible Party):
Stealth BioTherapeutics Inc.

Brief Summary:
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor to learn more about this program. The treating physician must contact StealthBiotherapeutics using the Expanded Access Program Contacts provided. Elamipretide will only be made available after careful review of an individual request submitted by the treating physician. The initiation and conduct of the treatment with elamipretide for an individual patient, and compliance with this treatment guideline, will be under the full and sole responsibility of the treating physician.

Condition or disease Intervention/treatment
Mitochondrial Diseases Barth Syndrome Drug: elamipretide

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Intermediate-size Population
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: An Intermediate Size Expanded Access Protocol of Elamipretide for Subcutaneous Injection in Patients With Genetically Confirmed Rare Diseases With Known Mitochondrial Dysfunction

Intervention Details:
  • Drug: elamipretide
    Elamipretide is an aromatic-cationic tetrapeptide that readily penetrates cell membranes and transiently localizes to the inner mitochondrial membrane.
    Other Name: MTP-131

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All

Key Inclusion Criteria:

  1. ≥1 year and ≤ 80 years of age or ≥12 years for Barth Syndrome in SPIES-007
  2. Patients with genetically confirmed rare primary mitochondrial diseases including Barth Syndrome

    1. observed cardiomyopathy, renal impairment, neuropathic, or ophthalmic manifestation
    2. where such disease is serious or life-threatening and no comparable or satisfactory alternative therapy options available.
  3. Patients without genetic confirmation of a rare disease with known mitochondrial dysfunction but do exhibit serious or life-threatening clinical manifestations of mitochondrial dysfunction.
  4. Is self-able or has caregiver willing and able to administer SC injection.
  5. Would potentially benefit from treatment with elamipretide and cannot be treated satisfactorily with any approved medicinal product in the opinion of the treating physician.

Key Exclusion Criteria:

  1. Known hypersensitivity to elamipretide or any excipients.
  2. Women who are pregnant, are planning on becoming pregnant, or are breast-feeding.
  3. Patients receiving any other investigational agent within 30 days of dosing.
  4. Any active, serious psychiatric, medical, or other conditions/situations which, in the treating physician's opinion, could compromise the patient's safety.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04689360

Layout table for location contacts
Contact: Donna Cowan 617.600.6888 donna.cowan@stealthbt.com
Contact: Donna Cowan access@stealthbt.com

Sponsors and Collaborators
Stealth BioTherapeutics Inc.
Layout table for additonal information
Responsible Party: Stealth BioTherapeutics Inc.
ClinicalTrials.gov Identifier: NCT04689360    
Other Study ID Numbers: SPIES-006
SPIES-007 ( Other Identifier: StealthBiotherapeutics )
First Posted: December 30, 2020    Key Record Dates
Last Update Posted: November 8, 2021
Last Verified: November 2021
Keywords provided by Stealth BioTherapeutics Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Barth Syndrome
Mitochondrial Diseases
Metabolic Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors